Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6). Gerilimzumab is promising for research of autoimmune diseases such as rheumatoid arthritis[1].
Target:
Interleukin Related
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
